Application and optimization of minimally invasive cell-free DNA techniques in oncogenomics

Area of Science:

• Oncology
• Molecular Diagnostics
• Biochemistry

Background:

• Conventional tissue biopsy for cancer biomarker analysis faces limitations due to tumor heterogeneity and invasiveness.
• Cell-free DNA (cfDNA) presents a non-invasive alternative for cancer diagnosis, prognosis, and therapy selection.
• Existing research shows cfDNA's utility in specific cancers like rectal and lung cancer, but broader application requires further investigation.

Purpose of the Study:

• To review critical preanalytical and analytical factors influencing the accuracy and reliability of cfDNA analysis for cancer biomarkers.
• To highlight the importance of optimizing cfDNA collection, storage, and processing for clinical utility.
• To emphasize the potential of liquid biopsy using cfDNA for identifying novel cancer biomarkers.

Main Methods:

• Literature review focusing on preanalytical variables in cfDNA isolation and analysis.
• Analysis of studies demonstrating cfDNA's role in various cancer types.
• Discussion of challenges and optimization strategies for cfDNA biomarker development.

Main Results:

• Preanalytical factors, including blood collection, sample stability, centrifugation, and plasma storage, significantly impact cfDNA analysis.
• The quantity of cfDNA is a critical consideration for biomarker detection.
• Standardized protocols are needed to ensure the accuracy and reproducibility of cfDNA-based cancer biomarkers.

Conclusions:

• Optimizing preanalytical and analytical procedures for cfDNA is essential for developing robust cancer biomarkers.
• Liquid biopsy using cfDNA holds significant potential to revolutionize cancer research and clinical practice.
• Standardized cfDNA analysis will facilitate the discovery of novel biomarkers for improved cancer diagnosis and treatment.